An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
NEJM study shows strong protection across strains
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
